Views
4
Objectives: Androgen deprivation therapy is the standard treatment for metastatic prostate cancer. Although the current treatment methods the disease becomes hormone resistant after a while. In our study, patients diagnosed with metastatic prostate cancer, we investigated the effects of modern treatment methods in terms of the clinical course and survival. Materials and Methods: Between 2005- 2012, 118 patients followed at our outpatient clinic with diagnosis of metastatic prostate cancer were retrospectively analyzed. Clinical characteristics, hormonal treatment modalities of patients, disease and treatment-related complications, disease progression and survival time were recorded. Results: The mean age of the patients at diagnosis was 69.4 53-87 years, mean PSA level before biopsy was 255.1 20-2000 ng / ml and the mean Gleason score was 8.1 7-10 . The mean hormone resistance development time in patients receiving hormonal therapy was 22.8 ± 10.9 months. The mean survival of patients with hormone resistant prostate cancer HRPC was 13.7 3-19 months. The mean time between the diagnose and death in metastatic prostate cancer patients was 36.6 ± 14.8 months. There was no statistical difference between neither monotherapy group LHRH therapy or orchidectomy and maximal androgen deprivation therapy group orchidectomy or LHRH therapy with antiandrogen drugs 35.7±12 months – 37.2±16.4 months, P=0.59 nor the intermittent hormonal therapy patients and continuous hormonal therapy given group 38±12.1 months - 35.5±16.7 months, P=0.35 in terms of mean survival rates. In patients receiving chemotherapy, the median survival was 7.4 months. Conclusion: Metastatic prostate cancer, when considering the disease itself as well as the side effects of treatment is a disease that requires careful treatment with the supportive therapy. Although metastatic prostate cancer is a hormone-sensitive tumor, intermittent or continuous hormonal therapy, MAB or monotherapy any of them are given, there are no differences in terms of survival.
Objectives: Androgen deprivation therapy is the standard treatment for metastatic prostate cancer. Although the current treatment methods the disease becomes hormone resistant after a while. In our study, patients diagnosed with metastatic prostate cancer, we investigated the effects of modern treatment methods in terms of the clinical course and survival. Materials and Methods: Between 2005-2012, 118 patients followed at our outpatient clinic with diagnosis of metastatic prostate cancer were retrospectively analyzed. Clinical characteristics, hormonal treatment modalities of patients, disease and treatment-related complications, disease progression and survival time were recorded. The average age of the patients at diagnosis was 69. 4 53-87 years, the average PSA level before biopsy was 255.1 20-2000 ng / ml and the average Gleason score was 8.1 7-10 . The average hormone resistance development time in patients receiving hormonal therapy was 22.8 ± 10.9 months. The average survival of patients with hormone resistant prostate cancer HRPC was 13.7 3-19 months. The average time between the diagnosis and death in metastatic prostate cancer patients was 36.6 ± 14.8 months. There was no statistical difference between any monotherapy group LHRH therapy or orchidectomy and maximum androgen deprivation therapy group orchidectomy or LHRH therapy with antiandrogen drugs 35.7±12 months - 37.2±16.4 months, P=0.59 nor the intermittent hormonal therapy patients and continuous hormonal therapy given group 38±12.1 months - 35.5±16.7 months, P=0. 35 in terms of average survival rates. In patients receiving chemotherapy, the median survival was 7.4 months. Metastatic prostate cancer, when considering the disease itself as well as the side effects of treatment is a disease that requires careful treatment with the supportive therapy. Although metastatic prostate cancer is a hormone-sensitive tumor, intermittent or continuous hormonal therapy, MAB or monotherapy any of them are given, there are no differences in terms of survival.
Article Detail 
Similar Articles
Journal Information
Listen Paper
Cite
Print This Page
Share
Mendeley
